Q1 FY 2027 saw record revenue and profit growth, led by a 69% surge in CDMO and 10% rise in Affordable Medicines. Margins expanded, CapEx guidance doubled to INR 2,000 crore, and the business remains well-diversified with strong global demand and robust outlook.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.